Short-term effects of Advograf plus Rapamiune after kidney transplant
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a combination of two medications (Advograf and Rapamiune) given shortly after kidney transplant to see how well they work and how safe they are. It may help improve long-term transplant health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received a kidney transplant (not kidney-pancreas).
- Your body mass index (BMI) is 30 or less.
- Your cPRA (a measure of immune sensitivity) is 0%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two diabetes medications, empagliflozin and linagliptin, to see which one works better for controlling blood sugar, protecting kidney function, and improving body composition in people who have had a kidney transplant and have diabetes.
This study follows older people who received a kidney transplant and are taking a specific immune-suppressing medicine plan (Advagraf/tacrolimus once daily plus mycophenolate and steroids). It may help researchers understand outcomes in real-world patients who match these medication and immune-risk criteria.
This trial tests a treatment approach for people who develop tremors after a combined pancreas and kidney transplant. It aims to improve tremor symptoms while keeping transplant organs functioning steadily.
This is a study of people who have a specific type of early rejection after a kidney transplant (“acute antibody-mediated rejection”). The study aims to understand what treatments work and why, to improve future care.
This trial is testing whether a blood test called Prospera can help doctors safely lower the amount of anti-rejection medicines you take after a kidney transplant. It is for people who recently received a kidney and are on standard anti-rejection drugs.
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
Hear when a new Kidney Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.